Summary:
Glenmark Pharmaceuticals reported a 56.8% YoY Q2FY27 profit decline to ₹263.83 crore, while underlying revenue grew around 20%. Shares rebounded 6.57% as the company retained FY27 revenue guidance of ₹17,000–18,000 crore and EBITDA margin guidance of 21–22%.
Glenmark Pharmaceuticals (NSE: GLENMARK | BSE: 532296) reported a 56.8% YoY decline in consolidated net profit for Q2FY27, yet retained its full-year revenue and margin guidance. The results, announced on November 5, showed a sharp fall in reported sales but a different picture after adjusting for licensing income.
What Happened in Q2FY27?
For the quarter ended September 30, 2026, consolidated revenue fell 29.8% YoY to ₹4,247.32 crore from ₹6,046.87 crore. Profit after tax (PAT) declined to ₹263.83 crore from ₹610.43 crore, while EBITDA stood at ₹863.8 crore, down 63.4%.
The EBITDA margin narrowed to 20.3% from around 39% a year earlier. Exceptional charges also affected the bottom line. After adjusting for these items, PAT stood at ₹485.2 crore, considerably above reported profit. Total expenses were ₹3,627.7 crore, against ₹3,895 crore in Q2FY26.
A legal settlement also featured in the quarter. The company's US subsidiary agreed to pay $15.28 mn to settle litigation involving Humana. It was a separate issue from everyday medicine sales but added to the need to distinguish exceptional items from underlying business performance.
Why the Headline Revenue Fall Needs Context
The year-ago quarter had unusually high revenue linked to the licensing of ISB 2001, a cancer drug candidate. This makes the reported YoY decline less useful for judging the ongoing medicines business.
On a like-for-like basis, consolidated revenue actually grew around 20% YoY. India's formulations business generated ₹1,327.4 crore, with comparable growth of ~14%. Emerging Markets revenue rose 33.2% to ₹876.9 crore, while Europe increased 6.2% to ₹792 crore.
North America reported ₹1,208.9 crore in revenue, a 72.9% YoY decline on paper. Excluding deferred ISB 2001 licensing income, however, the region's core business grew ~31%. Four new products were launched in North America during the quarter. The distinction matters because recurring product sales and licensing receipts have different earnings patterns.
Why Glenmark Shares Fell, Then Surged
The market reaction was anything but straightforward. On November 6, Glenmark opened at ₹2,375 on the BSE, down around 4.4% from the previous close of ₹2,485.50, following the weak headline results.
The stock then recovered sharply. By around 2:27 pm IST, it was trading near ₹2,648.90, up 6.57%, after touching a fresh 52-week high of ₹2,683.55.
The reversal came alongside details of underlying sales growth and unchanged annual guidance, although intraday prices can change quickly.
FY27 Guidance and What Comes Next
Glenmark kept its FY27 consolidated revenue guidance at ₹17,000–18,000 crore and EBITDA margin guidance at 21–22%. First-half revenue stood at approximately ₹8,265.8 crore. That leaves roughly ₹8,734–9,734 crore of revenue needed in H2FY27 to reach the stated range.
Product launches remain part of the company's growth plans. Respiratory treatment RYALTRIS is already marketed in 58 countries, with around 10 further market launches expected. The first commercial launch of oncology drug aumolertinib is also anticipated during H2FY27.
Still, guidance is not a guarantee. The key factors to monitor are whether North American product sales continue growing, operating margins improve towards the annual range and exceptional costs ease. Q2's reported decline was steep, but underlying business growth and the share-price rebound show why the headline numbers do not tell the whole story.
